AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$CADL

Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights • The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines

Original reporting
SEC EDGAR 8-K
Published Nov 12, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CADL
Bullish
high confidence
Mentioned
$CADL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CADLBullishHigh
01

Why it matters

The disclosed data may accelerate the path to BLA submission and improve cash‑runway confidence, influencing short‑term price dynamics.

02

Market read

Primary disclosure of earnings and pivotal clinical data for a small‑cap biotech, likely to move the stock on the day of release.

03

What to watch

Potential dilution from future financing needs if BLA approval is delayed.

Relevance 7/10Novelty 9/10Timing: today

Background

Candel Therapeutics is a clinical‑stage biopharma focused on multimodal immunotherapies. The 8‑K provides its first public disclosure of Q3 financials and recent trial outcomes.

Company-level read

Ticker impact

$CADLBullishHigh confidence
Context

Candel Therapeutics filed an 8‑K reporting Q3 2026 results and unveiling new Phase 2/3 clinical data for its aglatimagene and linoserpaturev programs.

Expected impact

likely upside as investors price in potential regulatory approval and expanded cash runway

Evidence & confidence

First‑report of material clinical outcomes and cash position; biotech stocks typically react strongly to such disclosures.

Market effects

Sector

strengthens the immunotherapy oncology sector with new data on gene‑therapy vectors

Regional

minimal regional effect; impact confined to US biotech investors

Global

limited to global biotech and gene‑therapy investors

Counterpoint

What could challenge this read

If the FDA raises additional CMC concerns, the stock could face pressure despite positive data.

Key entities

  • company
    Candel Therapeutics, Inc.

    Nasdaq‑listed biotech reporting Q3 results and trial updates.

  • executive
    Paul Peter Tak

    President and CEO of Candel Therapeutics, quoted in the filing.

Read at source← All news

Related articles

$CADLHigh

CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027

Candel Therapeutics (CADL) stock fell 38% after-hours after pushing back its FDA application for prostate cancer treatment to mid-2027. The company reported $203.1M in cash, expected to last until Q2 2028. Retail traders on Stocktwits remained bullish, with some suggesting the selloff could make the stock more attractive. CADL is up 48.5% year-to-date, according to the article.

finance.yahoo.com
$CADLMed

Candel Therapeutics, Inc. entered into a Second Amended and Restated Open Market Sale Agreement SM, with Jefferies LLC, to sell shares of the Company’s…

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Open Market Sale Agreement SM (the “2026 Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value

SEC EDGAR 8-K
$CADLMedAI 8/10

Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data

Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.

investing.com
$CADLHighAI 8/10

H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.

investing.com